SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-17-067405
Filing Date
2017-11-09
Accepted
2017-11-09 16:27:55
Documents
42
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q a17-20675_110q.htm 10-Q 863377
2 EX-10.1 a17-20675_1ex10d1.htm EX-10.1 33069
3 EX-31.1 a17-20675_1ex31d1.htm EX-31.1 11459
4 EX-31.2 a17-20675_1ex31d2.htm EX-31.2 11470
5 EX-32.1 a17-20675_1ex32d1.htm EX-32.1 8020
  Complete submission text file 0001104659-17-067405.txt   3051241

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT dova-20170930.xml EX-101.INS 340850
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dova-20170930.xsd EX-101.SCH 32926
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dova-20170930_cal.xml EX-101.CAL 24922
9 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT dova-20170930_lab.xml EX-101.LAB 321901
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dova-20170930_pre.xml EX-101.PRE 233470
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dova-20170930_def.xml EX-101.DEF 131632
Mailing Address 2530 MERIDIAN PARKWAY SUITE 300 DURHAM NC 27713
Business Address 2530 MERIDIAN PARKWAY SUITE 300 DURHAM NC 27713 919-806-4487
Dova Pharmaceuticals, Inc. (Filer) CIK: 0001685071 (see all company filings)

IRS No.: 813858961 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38135 | Film No.: 171191247
SIC: 2834 Pharmaceutical Preparations